Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The RASSF1A gene is a tumor suppressor gene inactivated by hypermethylation in a very wide variety of malignant tumors including prostate cancer. METHODS: In this study we have used laser capture microdissection to provide pure cell populations to investigate the methylation status of 16 CpG sites in the promoter region of this gene in prostatic intra-epithelial neoplasia, in histologically normal epithelial cells associated with these lesions and in epithelial cells from benign prostatic hyperplasia. RESULTS: Unexpectedly, frequent methylation, detected by sequence analysis following bisulphite treatment, was observed in benign epithelium as well as in the lesions associated with prostatic intra-epithelial neoplasia and at high risk of cancer formation. Fifty percent or more CpG sites were methylated in 7/14 prostatic intra-epithelial neoplasms, 8/11 histologically normal epithelial cells and 8/12 specimens of benign prostatic tissue. CONCLUSION: These observations suggest that methylation of the RASSF1A gene is present in both pre-malignant and benign epithelia and suggests quantitation is required for it to be an effective marker of early prostate cancer.

Original publication

DOI

10.1002/pros.20475

Type

Journal article

Journal

Prostate

Publication Date

01/05/2007

Volume

67

Pages

638 - 644

Keywords

Aged, Biomarkers, Tumor, Biopsy, Needle, CpG Islands, DNA Methylation, DNA, Neoplasm, Gene Silencing, Humans, Lasers, Male, Microdissection, Middle Aged, Precancerous Conditions, Promoter Regions, Genetic, Prostate, Prostatic Intraepithelial Neoplasia, Prostatic Neoplasms, Sequence Analysis, DNA, Tumor Suppressor Proteins